Pharmaceutical Industry
Filter News
Found 18,262 articles
-
Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation
10/22/2019
Stable Levels of Engraftment and Reconstitution of Enzyme Activity in Patients with Up to 12 Months of Follow-up Indicate Similar Profiles Between Cryopreserved and Fresh Formulations
-
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
10/22/2019
Webcast scheduled for Wednesday, November 6th at 11:30 a.m. Eastern Time
-
Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection
10/22/2019
Eton Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
-
CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer
10/22/2019
Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer
-
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results WebcastWebcast scheduled for Tuesday, November 5th at 4:30 p.m. Eastern Time
10/22/2019
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, November 5th at 4:30 p.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress..
-
Rhizen Pharmaceuticals S.A. announces poster presentations of RP7214, a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) in preclinical models of Acute Myeloid Leukemia (AML) at the 2019 AACR-NCI-EORTC Conference
10/22/2019
Rhizen Pharmaceuticals S.A. announces poster presentations of RP7214, a novel small molecule inhibitor of DHODH in preclinical models of Acute Myeloid Leukemia.
-
Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease
10/22/2019
Excellent Safety Profile and Improvements in Clinically Relevant Secondary Endpoints (Endoscopy and Histology) Support Further Development by a Partner
-
Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class store-operated calcium entry (SOCE) inhibitor in preclinical models of Acute Myeloid Leukemia (AML) at the 2019 AACR-NCI-EORTC Conference in Boston
10/22/2019
Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class SOCE inhibitor in preclinical models of Acute Myeloid Leukemia.
-
Altavant Sciences Presents Data at CHEST 2019 Supporting Once-Daily Dosing of Rodatristat Ethyl for the Treatment of Pulmonary Arterial Hypertension
10/22/2019
Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced mechanistic preclinical pharmacodynamic and Phase 1 data supporting once-daily dosing of rodatristat ethyl for the treatment of pulmonary arterial hypertension (PAH).
-
West Introduces NovaPure® 3mL Cartridge Components and Features SmartDose® Gen. II 10mL Drug Delivery System at PDA Universe of Pre-filled Syringes and Injection Devices
10/22/2019
Scientific Presentations & Trainings Highlight Scientific Leadership in Drug Containment & Delivery
-
TLC Reports Third Quarter 2019 Financial Results and Provides Business Update
10/22/2019
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the third quarter ended September 30, 2019, and provided a business update.
-
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
10/22/2019
New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints
-
ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
10/22/2019
Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis
-
Generational Priorities: What Baby Boomers, Gen-Xers and Millennials Think Makes an Ideal Employer
10/21/2019
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities. -
Clinical Catch-Up: October 14-18
10/21/2019
Last week was busy for clinical trial news. Here’s a look. -
Thanks to a new regulatory win, AstraZeneca’s Farxiga can now be used to reduce the risk of hospitalization for heart failure in type 2 diabetes patients with cardiovascular disease and with certain risk factors.
-
The approval is based on the Phase III UNIFI study that showed that after eight weeks of taking a single intravenous dose of Stelara, patients saw “clinical remission in a significantly greater proportion of UC patients.”
-
Promore Pharma engages ABG Sundal Collier as liquidity provider
10/21/2019
Promore Pharma AB announced that the company has entered into an agreement with ABG Sundal Collier ASA whereby ABGSC will act as liquidity provider for the Promore Pharma share starting 21 October.
-
Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRA
10/21/2019
Santhera Pharmaceuticals announces that the UK’s Medicines and Healthcare Products Regulatory Agency has informed ReveraGen BioPharma about having designated vamorolone as Promising Innovative Medicine for the treatment of Duchenne muscular dystrophy
-
Arcutis Announces the Completion of $94.5 million Series C Financing
10/21/2019
HBM Healthcare Investments, Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs join existing investors Frazier Healthcare Partners, Bain Capital Life Sciences, OrbiMed and RA Capital Management